Can “Botox in a bottle” really rival injectable neuromodulators? We examine the evidence behind topical peptide serums and Argireline.
News|Articles|June 23, 2025
Daily Derm Times: June 23, 2025
Author(s)Emma Andrus, Editor
Listen
0:00 / 0:00
Key Takeaways
- Dr. Iris Rubin's SEEN brand innovatively addresses acne through skin-friendly hair care formulations, enhancing skin health.
- Broc Vargo advocates for sun safety, driven by his personal experiences, emphasizing public health education.
Catch up on dermatology news, highlights, and insights from the past 24 hours.
Advertisement
To stay up-to-date with the latest dermatology news, sign up to receive our
Acne Awareness Month: The Link Between Hair Care and Skin Health
Iris Rubin, MD, reveals how her brand SEEN transforms hair products to combat acne, promoting clearer skin through innovative, skin-friendly formulations.
Derm Dispatch: Pre-Med Student Champions Sun Safety Through Advocacy and Education
UC Berkeley’s Broc Vargo shares how growing up in tanning salons inspired his passion for dermatology, sun safety, and public health advocacy.
How Hair Care is an Extension of Skin Care, According to Iris Rubin, MD
Iris Rubin, MD, highlights SEEN's science-backed hair care, designed for acne-prone skin, improving scalp health and reducing irritation.
Pelage's PP405 Demonstrates Efficacy in Phase 2a Trial for Androgenetic Alopecia
PP405 shows promise for hair regrowth in phase 2a trial, with 31% seeing >20% density increase; phase 3 studies are planned for 2026.
Advertisement
Related to this article
New indications for superficial basal cell carcinoma and adolescent alopecia areata expanded treatment options, while psoriasis and rare disease candidates advanced through FDA review.
The novel oral helicase-primase inhibitor demonstrated significantly higher rates of complete lesion healing compared with investigator’s choice treatment in the phase 3 PRIOH-1 trial.
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
Galderma has agreed to acquire ZO Skin Health for $1.5 billion, adding the physician-dispensed skincare brand to a portfolio that already includes Cetaphil and Alastin.
New dermatology research explores hidden steroids in OTC products, infant eczema, melanoma prevention, cutaneous lymphoma, and pediatric AD.
SYX-5219 improved disease severity and itch in a Phase 1b trial of adults with moderate to severe atopic dermatitis.
Advertisement
Advertisement
Trending on Dermatology Times
1
Galderma to Acquire ZO Skin Health for $1.5 Billion
2
FDA Approves Pritelivir for Refractory Mucocutaneous HSV in Immunocompromised Adults
3
Q&A: Falk G. Bechara, MD, on Long-Term Tunnel Control and Structural Damage in HS
4
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
5